New Case Western Reserve research identifies local hotspots and links environmental factors like extreme heat to increased ...

Glucagon-like peptide-1 receptor agonist therapy is associated with a reduced risk for epilepsy in adults with type 2 diabetes mellitus.

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Emerging clinical and autopsy evidence points to late-onset epilepsy as a potentially distinct, neurodegeneration-related ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

ORLANDO — A new review adds to growing evidence that the modified Atkins diet (MAD) significantly reduces seizures in adults with drug-resistant epilepsy. Dr Aiswarya Raj The results of the small new ...

A new analysis suggests GLP 1 receptor agonists, the diabetes drugs that include semaglutide, dulaglutide and liraglutide, ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Individuals with epilepsy and their caregivers want improved communication and a broader base of information from their ...

A recent study points to a potential link between GLP-1 drugs and its ability to reduce risk of epilepsy in people with type 2 diabetes. GLP-1 drugs (semaglutide) are those which mimic the function of ...

Moving forward The CDC reports that one in 100 U.S. adults has active epilepsy, and studies suggest that one third of these are not receiving adequate treatment or care. 30 Although this recent report ...